AbbVie Inc. (ABBV) Key Metrics
ABBV valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $504.37B
- Enterprise value
- $532.68B
- P/E (TTM)
- 80.6 10-yr median 27.1
- Forward P/E
- 16.4
- PEG ratio
- 0.54
- Price / sales
- 7.8 10-yr median 4.7
- Price / book
- 50.5 10-yr median 22.0
- EV / EBITDA
- 27.3 10-yr median 18.2
- Dividend yield
- 2.42% $6.92 a year
- Beta
- 0.23
ABBV key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsABBV valuation Price multiples at each fiscal year-end price.
ABBV returns How much profit the business earns on the capital it uses.
ABBV per-share figures Results divided by the shares outstanding at year-end.
ABBV financial health Debt, liquidity and how easily interest is covered.
ABBV efficiency & capital use Working capital cycle and where the cash goes.
ABBV valuation history
ABBV returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ABBV debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ABBV cash returned to shareholders
ABBV price vs earnings per share
ABBV key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $405.34B | $315.06B | $274.76B | $287.34B | $240.61B | $179.26B | $131.39B | $142.53B | $155.03B | $102.13B |
| Enterprise value | $469.15B | $377.35B | $322.07B | $342.30B | $308.35B | $257.85B | $158.56B | $174.77B | $182.61B | $132.55B |
| P/E ratio | 95.9 | 73.6 | 56.5 | 24.3 | 20.8 | 38.8 | 16.7 | 25.1 | 29.2 | 17.2 |
| Price / sales | 6.6 | 5.6 | 5.1 | 4.9 | 4.3 | 3.9 | 3.9 | 4.4 | 5.5 | 4.0 |
| Price / book | — | 93.7 | 26.4 | 16.6 | 15.6 | 13.7 | — | — | 30.4 | 22.0 |
| Price / free cash flow | 22.8 | 17.7 | 12.5 | 11.9 | 10.9 | 10.7 | 10.3 | 11.1 | 16.4 | 15.6 |
| Price / operating cash flow | 21.3 | 16.8 | 12.0 | 11.5 | 10.6 | 10.2 | 9.9 | 10.6 | 15.6 | 14.5 |
| EV / sales | 7.7 | 6.7 | 5.9 | 5.9 | 5.5 | 5.6 | 4.8 | 5.3 | 6.5 | 5.2 |
| EV / EBITDA | 26.6 | 25.3 | 18.8 | 14.2 | 12.9 | 20.9 | 13.0 | 21.0 | 17.6 | 13.1 |
| EV / free cash flow | 26.3 | 21.2 | 14.6 | 14.1 | 14.0 | 15.4 | 12.4 | 13.7 | 19.4 | 20.2 |
| Earnings yield | 1.0% | 1.4% | 1.8% | 4.1% | 4.8% | 2.6% | 6.0% | 4.0% | 3.4% | 5.8% |
| Free cash flow yield | 4.4% | 5.7% | 8.0% | 8.4% | 9.1% | 9.4% | 9.7% | 9.0% | 6.1% | 6.4% |
| Dividend yield | 2.9% | 3.5% | 3.8% | 3.5% | 3.8% | 4.3% | 4.8% | 3.9% | 2.6% | 3.6% |
| Shareholder yield (dividends + buybacks) | 3.1% | 4.0% | 4.6% | 4.0% | 4.2% | 4.8% | 5.3% | 12.3% | 3.6% | 9.5% |
| Share price at fiscal year-end | $228.49 | $177.70 | $154.97 | $161.61 | $135.40 | $107.15 | $88.54 | $92.19 | $96.71 | $62.62 |
| Per share | ||||||||||
| Revenue per share | $34.48 | $31.77 | $30.64 | $32.65 | $31.62 | $27.38 | $22.42 | $21.19 | $17.60 | $15.72 |
| Earnings per share | $2.38 | $2.41 | $2.74 | $6.66 | $6.50 | $2.76 | $5.31 | $3.68 | $3.31 | $3.65 |
| Operating cash flow per share | $10.73 | $10.61 | $12.88 | $14.03 | $12.82 | $10.51 | $8.98 | $8.68 | $6.21 | $4.32 |
| Free cash flow per share | $10.04 | $10.06 | $12.44 | $13.64 | $12.37 | $10.04 | $8.61 | $8.27 | $5.88 | $4.02 |
| Cash per share | $2.96 | $3.13 | $7.23 | $5.19 | $5.53 | $5.07 | $26.90 | $5.21 | $6.11 | $3.94 |
| Book value per share | −$1.82 | $1.90 | $5.86 | $9.72 | $8.69 | $7.83 | −$5.51 | −$5.46 | $3.18 | $2.84 |
| Tangible book value per share | −$51.58 | −$51.70 | −$43.71 | −$46.29 | −$52.28 | −$61.51 | −$28.59 | −$29.33 | −$23.86 | −$24.33 |
| Dividends per share | $6.57 | $6.22 | $5.94 | $5.65 | $5.21 | $4.61 | $4.29 | $3.61 | $2.56 | $2.28 |
| Capex per share | $0.68 | $0.55 | $0.44 | $0.39 | $0.44 | $0.48 | $0.37 | $0.41 | $0.33 | $0.29 |
| Debt per share | $38.93 | $38.26 | $33.91 | $36.10 | $43.66 | $52.04 | $45.21 | $26.07 | $23.31 | $22.59 |
| Shares outstanding | 1.77B | 1.77B | 1.77B | 1.78B | 1.78B | 1.67B | 1.48B | 1.55B | 1.60B | 1.63B |
| Change in shares outstanding | +0.1% | 0.0% | −0.3% | +0.1% | +6.2% | +12.7% | −4.0% | −3.6% | −1.7% | −0.4% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | 62.2% | 35.1% | 72.3% | 80.9% | 187.5% | — | — | 109.1% | 138.7% |
| Return on invested capital (ROIC) | 20.4% | 14.8% | 15.3% | 20.5% | 18.2% | 20.5% | 56.8% | 22.6% | 19.4% | 22.7% |
| Return on assets (ROA) | 3.1% | 3.2% | 3.6% | 8.3% | 7.8% | 3.9% | 10.6% | 8.7% | 7.8% | 10.0% |
| Return on tangible assets | 9.3% | 10.7% | 10.4% | 30.2% | 30.2% | 13.4% | 14.4% | 25.3% | 19.3% | 27.3% |
| Free cash flow margin | 29.1% | 31.7% | 40.6% | 41.8% | 39.1% | 36.7% | 38.4% | 39.0% | 33.4% | 25.6% |
| Income quality (OCF / net income) | 4.50 | 4.40 | 4.70 | 2.11 | 1.97 | 3.81 | 1.69 | 2.36 | 1.88 | 1.18 |
| Financial health | ||||||||||
| Total debt | $69.07B | $67.84B | $60.12B | $64.19B | $77.58B | $87.06B | $67.09B | $40.31B | $37.37B | $36.84B |
| Cash & short-term investments | $5.26B | $5.55B | $12.82B | $9.23B | $9.83B | $8.48B | $39.92B | $8.06B | $9.79B | $6.42B |
| Net debt | $63.81B | $62.29B | $47.30B | $54.96B | $67.75B | $78.58B | $27.16B | $32.25B | $27.58B | $30.42B |
| Debt / equity | — | 20.17 | 5.78 | 3.71 | 5.03 | 6.65 | — | — | 7.33 | 7.95 |
| Debt / assets | 0.52 | 0.50 | 0.45 | 0.46 | 0.53 | 0.58 | 0.75 | 0.68 | 0.53 | 0.56 |
| Net debt / EBITDA | 3.62 | 4.18 | 2.75 | 2.27 | 2.83 | 6.38 | 2.22 | 3.88 | 2.66 | 3.01 |
| Current ratio | 0.67 | 0.66 | 0.87 | 0.96 | 0.79 | 0.84 | 3.18 | 0.98 | 1.28 | 1.65 |
| Quick ratio | 0.56 | 0.55 | 0.76 | 0.84 | 0.70 | 0.73 | 3.06 | 0.89 | 1.18 | 1.51 |
| Interest coverage | 6.9 | 3.3 | 5.7 | 8.1 | 7.4 | 4.6 | 7.3 | 4.7 | 8.3 | 8.9 |
| Working capital | −$14.23B | −$13.17B | −$4.84B | −$1.07B | −$7.27B | −$4.49B | $33.93B | −$294.0M | $4.58B | $6.41B |
| Invested capital | $60.58B | $65.65B | $57.70B | $72.25B | $83.18B | $91.68B | $18.99B | $23.80B | $32.68B | $35.05B |
| Tangible asset value | −$91.51B | −$91.66B | −$77.51B | −$82.31B | −$92.89B | −$102.90B | −$42.42B | −$45.34B | −$38.25B | −$39.68B |
| Net current asset value | −$108.13B | −$106.22B | −$91.31B | −$93.06B | −$103.17B | −$113.30B | −$47.77B | −$50.85B | −$44.47B | −$45.28B |
| Graham number | — | $10.15 | $19.02 | $38.16 | $35.63 | $22.05 | — | — | $15.39 | $15.28 |
| Graham net-net per share | −$67.65 | −$65.40 | −$57.01 | −$57.40 | −$63.15 | −$72.16 | −$35.30 | −$35.51 | −$31.99 | −$31.12 |
| Capital allocation | ||||||||||
| Dividends paid | $11.66B | $11.03B | $10.54B | $10.04B | $9.26B | $7.72B | $6.37B | $5.58B | $4.11B | $3.72B |
| Share buybacks (net) | $980.0M | $1.71B | $1.97B | $1.49B | $934.0M | $978.0M | $629.0M | $12.01B | $1.41B | $6.03B |
| Dividend payout ratio | 275.8% | 257.7% | 216.7% | 84.9% | 80.2% | 167.2% | 80.8% | 98.1% | 77.4% | 62.4% |
| Dividends + buybacks / free cash flow | 70.9% | 71.4% | 56.7% | 47.6% | 46.4% | 51.8% | 54.8% | 137.6% | 58.5% | 148.6% |
| Capex / revenue | 2.0% | 1.7% | 1.4% | 1.2% | 1.4% | 1.7% | 1.7% | 1.9% | 1.9% | 1.9% |
| Capex / operating cash flow | 6.4% | 5.2% | 3.4% | 2.8% | 3.5% | 4.5% | 4.1% | 4.8% | 5.3% | 6.8% |
| Capex / depreciation | 0.15 | 0.12 | 0.09 | 0.08 | 0.09 | 0.12 | 0.27 | 0.36 | 0.35 | 0.40 |
| Stock-based compensation / revenue | 1.6% | 1.6% | 1.4% | 1.2% | 1.2% | 1.6% | 1.3% | 1.3% | 1.3% | 1.4% |
| R&D / revenue | 14.9% | 22.7% | 14.1% | 11.2% | 14.3% | 16.9% | 20.4% | 32.8% | 18.9% | 17.9% |
| SG&A / revenue | 22.9% | 23.4% | 23.8% | 26.3% | 22.0% | 21.5% | 17.6% | 22.4% | 22.1% | 22.8% |
| Efficiency | ||||||||||
| Days sales outstanding | 70.1 | 71.5 | 75.3 | 66.7 | 61.0 | 56.8 | 59.3 | 58.4 | 63.7 | 67.5 |
| Days of inventory on hand | 91.6 | 89.4 | 68.6 | 70.3 | 67.3 | 60.8 | 83.9 | 75.9 | 79.0 | 99.0 |
| Days payables outstanding | 65.5 | 71.6 | 59.2 | 61.0 | 54.0 | 44.2 | 73.5 | 71.4 | 74.7 | 94.0 |
| Cash conversion cycle (days) | 96.2 | 89.3 | 84.7 | 76.1 | 74.4 | 73.3 | 69.6 | 62.8 | 68.0 | 72.5 |
| Receivables turnover | 5.20 | 5.10 | 4.85 | 5.47 | 5.98 | 6.43 | 6.15 | 6.26 | 5.73 | 5.40 |
| Payables turnover | 5.57 | 5.10 | 6.17 | 5.99 | 6.76 | 8.25 | 4.96 | 5.11 | 4.89 | 3.88 |
| Inventory turnover | 3.99 | 4.08 | 5.32 | 5.19 | 5.42 | 6.01 | 4.35 | 4.81 | 4.62 | 3.69 |
| Asset turnover | 0.45 | 0.42 | 0.40 | 0.41 | 0.38 | 0.38 | 0.45 | 0.50 | 0.41 | 0.43 |
| Average receivables | $11.75B | $11.04B | $11.20B | $10.62B | $9.40B | $7.12B | $5.41B | $5.24B | $4.92B | $4.74B |
| Average payables | $3.27B | $3.32B | $3.31B | $2.91B | $2.58B | $1.86B | $1.50B | $1.51B | $1.44B | $1.50B |
| Average inventory | $4.57B | $4.14B | $3.84B | $3.35B | $3.22B | $2.56B | $1.71B | $1.60B | $1.52B | $1.58B |
| Intangibles / total assets | 65.9% | 70.3% | 65.3% | 71.8% | 73.9% | 77.0% | 38.4% | 62.2% | 61.2% | 67.0% |
Computed from ABBV's annual financial statements (latest annual report filed February 20, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ABBV valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), AbbVie traded at 95.9 times earnings, against a 10-year median of 27.1. Based on the latest twelve months, the trailing P/E is 80.6 and the forward P/E is 16.4. AbbVie earned a return on invested capital of 20.4% in fiscal 2025. It ended the year with $69.1 billion of debt and $5.3 billion in cash and short-term investments, net debt of $63.8 billion. It returned $12.6 billion to shareholders: $11.7 billion in dividends and $980.0 million in share buybacks, 71% of free cash flow. The share count rose 8.8% from 1.63B to 1.77B over 9 years.
See the ABBV income statement, the ABBV chart for price history, or the ABBV stock overview for the latest quote and news.
ABBV key metrics FAQ
What is AbbVie's P/E ratio?
AbbVie's trailing P/E ratio is 80.6 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 16.4. At the end of fiscal 2025 it was 95.9, compared with a 10-year median of 27.1.
What is AbbVie's EV/EBITDA?
AbbVie's enterprise value was 26.6 times EBITDA at the end of fiscal 2025 (enterprise value $469.2 billion, EBITDA $17.6 billion); the current EV/EBITDA is 27.3.
What is AbbVie's ROIC?
AbbVie's return on invested capital was 20.4% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does AbbVie have?
AbbVie had total debt of $69.1 billion at the end of fiscal 2025 and $63.8 billion of net debt (3.62 times EBITDA).
What is AbbVie's dividend yield?
AbbVie's forward dividend yield is 2.42%. AbbVie paid $11.7 billion in dividends in fiscal 2025 ($6.57 per share), a payout ratio of 275.8%.
Does AbbVie buy back its shares?
Yes. AbbVie spent $980.0 million on net share repurchases in fiscal 2025 Shares outstanding changed +0.1% over the year, to 1.77B..
What is AbbVie's free cash flow yield?
AbbVie generated $17.8 billion of free cash flow in fiscal 2025, a free cash flow yield of 4.4% on its market value at year-end ($405.3 billion).
What is AbbVie's current ratio?
AbbVie's current ratio was 0.67 at the end of fiscal 2025: current assets were 0.67 times current liabilities.